Research and Advances in Care for Sickle Cell Disease Patients

Blood disorders such as sickle cell disease and thalassemia have profound, lifelong effects on patients and their families. Accurate coding of these conditions is essential for tracking disease prevalence, evaluating outcomes, and measuring the impact of emerging therapies and protocols.

About sickle cell disease

In the United States, an estimated 20,000 people are living with severe sickle cell disease, an inherited hemoglobin disorder in which red blood cells form rigid, crescent (sickle) shapes rather than the normal biconcave disc. These misshapen cells can obstruct small blood vessels, leading to reduced blood flow, tissue ischemia, and severe pain episodes known as acute vaso occlusive crises. Management may include avoidance of triggers, aggressive pain control, and transfusion therapy when crises occur.

Research holds the key to sickle cell

Research into curative and disease modifying treatments is accelerating, with encouraging early results.
A recent multicenter trial, for example, evaluated a single administration CRISPR based gene edited therapy (reni cel, an autologous gene edited stem cell product) in 28 patients with severe sickle cell disease; 27 of these patients experienced no painful sickle cell crises after treatment, representing a “functional cure” for most participants.  (The results of the trial were published April 1, 2026 in the New England Journal of Medicine).

Coding of sickle cell disease

Advances in the treatment of sickle cell depend on precise coding of both underlying conditions and associated complications. Sickle cell disease may occur alone or in combination with thalassemia, and vaso occlusive events can manifest as acute chest syndrome, splenic sequestration, or pain crises affecting multiple body sites.

As coders, our obligation is to ensure accurate code assignment for sickle cell disease, capturing both presentation and crisis type. Many new therapies are being introduced and can be reported with New Technology ICD-10-PCS codes offering significant financial benefit to healthcare organizations.  (For more information on these New Technology codes see NTAP Coding Challenge: Sickle Cell Disease Treatment Provides New Hope, written by Lynn Kuehn, MS, RHIA, CCS-P, FAHIMA.)

As novel therapies and treatment strategies emerge, high quality coding allows improvements in patient outcomes to be reflected in the data through precise condition and crisis codes.

ICD 10 CM: Coding Blood and Immune Disorders
Intensive skills training in the guidelines and rules governing correct coding of sickle cell disease, thalassemia, and a broad range of blood and immune disorders, using real world case documentation to help learners master coding of these complex scenarios.

Written by nationally-recognized coding authority, Therese (Teri) Jorwic, MPH, RHIA, CCS, CCS-P, FAHIMA, the course covers the diagnoses most likely to challenge coders. More info